BRPI0813833A2 - Anticorpos antagonistas de receptor-1 ativado por protease (par1) - Google Patents
Anticorpos antagonistas de receptor-1 ativado por protease (par1)Info
- Publication number
- BRPI0813833A2 BRPI0813833A2 BRPI0813833-8A2A BRPI0813833A BRPI0813833A2 BR PI0813833 A2 BRPI0813833 A2 BR PI0813833A2 BR PI0813833 A BRPI0813833 A BR PI0813833A BR PI0813833 A2 BRPI0813833 A2 BR PI0813833A2
- Authority
- BR
- Brazil
- Prior art keywords
- par1
- protease
- activated receptor
- antagonist antibodies
- antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95029007P | 2007-07-17 | 2007-07-17 | |
| PCT/US2008/070357 WO2009012401A1 (en) | 2007-07-17 | 2008-07-17 | Antagonist antibodies of protease activated receptor-1 (par1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0813833A2 true BRPI0813833A2 (pt) | 2015-01-06 |
Family
ID=39810256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0813833-8A2A BRPI0813833A2 (pt) | 2007-07-17 | 2008-07-17 | Anticorpos antagonistas de receptor-1 ativado por protease (par1) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100330090A1 (pt) |
| EP (1) | EP2176297A1 (pt) |
| JP (1) | JP2010533732A (pt) |
| KR (1) | KR20100021657A (pt) |
| CN (1) | CN101977936A (pt) |
| AU (1) | AU2008275992A1 (pt) |
| BR (1) | BRPI0813833A2 (pt) |
| CA (1) | CA2693201A1 (pt) |
| EA (1) | EA201000102A1 (pt) |
| WO (1) | WO2009012401A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014152715A1 (en) * | 2013-03-15 | 2014-09-25 | University Of Rochester | Use of inhibitors of binding between a par-1 receptor and its ligands for the treatment of glioma |
| WO2025056909A1 (en) * | 2023-09-15 | 2025-03-20 | Antiverse Ltd | Binding molecules |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003526625A (ja) * | 1999-07-23 | 2003-09-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 血小板の活性化の調節 |
| EP1603947A1 (en) * | 2003-03-11 | 2005-12-14 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with g-protein coupled protease activated receptor 1 (par1) |
| AU2005207003C1 (en) * | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| AU2005306502B2 (en) * | 2004-11-16 | 2012-11-15 | Humanigen, Inc. | Immunoglobulin variable region cassette exchange |
| US7888483B2 (en) * | 2006-07-18 | 2011-02-15 | Irm Llc | Antagonists of protease activated receptor-1 (PAR1) |
-
2008
- 2008-07-17 US US12/669,467 patent/US20100330090A1/en not_active Abandoned
- 2008-07-17 KR KR1020107000982A patent/KR20100021657A/ko not_active Ceased
- 2008-07-17 EP EP08826361A patent/EP2176297A1/en not_active Withdrawn
- 2008-07-17 WO PCT/US2008/070357 patent/WO2009012401A1/en not_active Ceased
- 2008-07-17 AU AU2008275992A patent/AU2008275992A1/en not_active Abandoned
- 2008-07-17 JP JP2010517164A patent/JP2010533732A/ja active Pending
- 2008-07-17 CN CN2008800248245A patent/CN101977936A/zh active Pending
- 2008-07-17 EA EA201000102A patent/EA201000102A1/ru unknown
- 2008-07-17 CA CA2693201A patent/CA2693201A1/en not_active Abandoned
- 2008-07-17 BR BRPI0813833-8A2A patent/BRPI0813833A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009012401A1 (en) | 2009-01-22 |
| AU2008275992A1 (en) | 2009-01-22 |
| US20100330090A1 (en) | 2010-12-30 |
| CA2693201A1 (en) | 2009-01-22 |
| KR20100021657A (ko) | 2010-02-25 |
| EP2176297A1 (en) | 2010-04-21 |
| CN101977936A (zh) | 2011-02-16 |
| EA201000102A1 (ru) | 2010-12-30 |
| JP2010533732A (ja) | 2010-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2066695T3 (da) | Anti-myostatin-antistoffer | |
| HRP20151108T1 (xx) | Antagonisti nogo-receptora | |
| DK1891911T3 (da) | Linseisættelsessystem | |
| BRPI0814252A2 (pt) | Formulações de anticorpo | |
| PT2889310T (pt) | Formulações de anticorpo | |
| BRPI0715712A2 (pt) | Composição farmacêutica | |
| NL2000480A1 (nl) | Nieuwe farmaceutische middelen. | |
| ATE443753T1 (de) | Nuancierungsmittel | |
| EP2215246A4 (en) | PROTEIN SCAFFOLDS | |
| ATE524493T1 (de) | Exendin-fusionsproteine | |
| BRPI0719393A2 (pt) | Composição farmacêutica | |
| DK2081951T3 (da) | Progesteron-receptorantagonister | |
| BRPI0820819A2 (pt) | Formulação de anticorpos | |
| EP1942028A4 (en) | SEAT | |
| EP1944192A4 (en) | SEAT | |
| BRPI0814111A2 (pt) | Anticorpo monoclonal citotóxico anticâncer | |
| BRPI0720234A2 (pt) | Composição farmacêutica | |
| EP2008963A4 (en) | SEAT | |
| EP2010561A4 (en) | ANTIMICROBIAL PEPTIDES | |
| DE602007010950D1 (de) | Dosierpumpe | |
| FI7098U1 (fi) | Kaidejärjestelmä | |
| EP2101804A4 (en) | PROANGIOGENIC PEPTIDES | |
| EP2214719A4 (en) | Metallofullerene-DYE | |
| ATE530564T1 (de) | Peptid-komplement-konjugate | |
| DK2021364T3 (da) | Forbedrede antimikrobielle peptider |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |